A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00134498|
Recruitment Status : Completed
First Posted : August 24, 2005
Last Update Posted : November 16, 2007
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.
|Condition or disease||Intervention/treatment||Phase|
|Hypertriglyceridemia Hyperlipoproteinemia Type IV||Drug: torcetrapib/atorvastatin Drug: atorvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia|
|Study Start Date :||February 2005|
|Study Completion Date :||November 2006|
- Change in HDL-C and non-HDL-C levels
- Changes in levels of other lipid and biomarkers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00134498
Show 44 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|